Aug. 2 at 2:41 PM
$IART quick and dirty margin of safety (mos)analysis : they bought Codman for 2.7 x sales back in 2017. Let’s apply 1/2 that multiple to that segment and 1x for the rest .
Total rev 2025: 1,680
Codman is 70%:
$1176 x1.35 =
$1,587.60
Tissue is 30%:
$504 x1.00=
$504
Cash on hand:
$250
Company MOS value: 2,350m
—————-
Ev:
$1500 net debt plus 77m shares at
$12=
$2,400
Forecast
$2.20 eps 2025 = 5.5 times earnings 
Therefore- I’d say
$12 and under is a great bargain. If the can avoid additional ship holds we’ll be much higher as IV is probably in the mid
$20S with mid single growth and fda concerns dissipating 🤞
